Business Wire

Historic Partnership between the Weizmann Institute of Science and Institut Curie

25.3.2019 19:54:00 EET | Business Wire | Press release

Share

On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics.

Collaborative research programs

This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot. Each research program will be organized around a pair of researchers with a scientist from Institut Curie and a scientist from the Weizmann Institute of Sciences, who will receive support on the annual basis. This partnership also includes exchanges of scientists and a Curie-Weizmann symposium organized every two years, with alternate locations in Rehovot, Israel, and in Paris, which will be focused on one of the subjects of research cooperation.
To finance the start of this cooperation, Institut Curie and the Weizmann Institute of Sciences will finance this research program for €200,000 each, and will organize a joint fundraiser with philanthropists and corporate sponsors.

Projects with high hopes
There are numerous common interests between the two Institutes. They can range from the description of defects in cell nuclei to the mechanics of cell migration, or the behavior of neural networks. A few examples of exciting ongoing projects are highlighted below.
During his sabbatical visit at Institut Curie in 2012, Professor Nir Gov (Weizmann Institute) participated in several projects ranging from cell migration to collective cell behaviors and neuron growth. For instance, he developed a theory in collaboration with Raphael Voituriez (Sorbonne University), which explains the observations of the team of Matthieu Piel (Institut Curie) on the links between persistence and speed of migrating cells. This theory gave rise to collaborative developments between these three teams to predict important aspects of the migratory behavior of immune cells.
He also collaborated with Pascal Silberzan at Institut Curie to understand the behavior of cells packed at very high density on a surface. This joint work combining experiments and theory, has highlighted the importance of an intrinsic biological ageing of the cell population. This project has helped understanding how cells can come to an arrest while maintaining a capacity to respond to external perturbations such as an injury.
Elisha Moses (Weizmann Institute) has a longstanding interaction with the group of Professor Jean-Louis Viovy (Institut Curie), now headed by Stéphanie Descroix, on the applications of microfluidic devices to the study of living neuronal networks. He spent three months in Paris, during which he and Dr. Catherine Villard of the Descroix lab developed an optogenetic assay for guiding axonal growth. This work has the potential for controlling growth of neurons and of neuronal tumors within the brain. Drs. M. Vignes and R. Renault, two talented researchers who were working on the project as students, have now graduated and branched off into very interesting conceptual and practical applications of this approach.

An important complementarity
The two institutions are both highly complementary and display many mutually common attributes.
Institut Curie is the premier research center in France conducting cancer research, including all facets of carcinogenesis. Its research center brings together 1,200 researchers working in 12 joint research units organized in four areas based on natural scientific interactions and robust medical potentiality. A strong advocate of international cooperation , it welcomes more than 80 nationalities. Equipped with advanced technology platforms, it is an important resource for researchers around the world. Institut Curie is also a state-of-the-art hospital complex that provides care and support for all cancer types and welcomes more than 50,000 patients each year. It has developed particularly innovative treatments directly from the work of its research center. Institut Curie also trains students in science and cancer research with the goal of increasing the knowledge about the topic.
The Weizmann Institute of Science is among the ten premier institutes of fundamental research in the world: 2,500 scientists work on its campus in Rehovot in the complementary fields of mathematics and computer science, physics, biology, chemistry, and biochemistry. The Weizmann Institute of Science has a long history of research and discoveries rooted in a mission of advancement of science for the benefit of humanity; cancer research accounts for 40% of the total budget of the Institute, which shapes and hosts a large part of the leadership in Israel and contributes to the advancement and understanding of scientific issues among all audiences.
Both institutions have powerful means of technology transfer that leverage the discoveries of their labs for the benefit of patients, whether through the creation of medications, medical devices or other technologies.

A shared vision of science
Science at the service of people - this is the best way to describe the credo of the two institutes, both of which were founded upon great personalities who have made an important mark in the history of the world.
Chaim Weizmann, chemist and author of many discoveries and publications, is the founder of the Weizmann Institute, and was the first president of the State of Israel between 1949 and 1952. Marie Curie, born Maria Sklodowska, founded the Radium Institute in 1909. The first female professor and holder of a chair position at the Sorbonne, the first woman to win two Nobel prizes and be enshrined at the Pantheon in Paris on her own merit. In many ways, these two scientists have had a remarkable journey.
But beyond these prestigious founders, the two institutes share the same vision of science, at the service of people and driven by strong values, the same curiosity for discovery and knowledge at the service of human health.
The Weizmann Institute of Science and Institut Curie also share a common belief that international collaborations in the field of institut-curie.org science and the exchange of ideas across interdisciplinary boundaries can accelerate progress to the benefit of humanity.
It is this common ground which today enables this collaboration to take root and which will tomorrow allow us to multiply efforts and as a result enjoy major new discoveries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Yohan Philippe
yohan.philippe@curie.fr
+33 (0)1 56 24 55 53

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 16:17:00 EET | Press release

Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candidates designed to target the underlying biology of canine aging and help dogs live longer, healthier lives alongside the people who love them. LOY-003 i

NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 16:08:00 EET | Press release

NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261115196647/en/ NIKE, Inc. is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. Elite marathoners. Backyard hoopers. An athlete* walking into the gym for the first time. Every athlete NIKE, Inc. works alongside pushes the company to imagine what doesn’t yet exist, then make those possibilities real. Today, NIKE, Inc. is showing what comes next. As part of its World of Athletes* showcase in Beaverton, Ore., the company is unveiling Tuned Air, the next frontier of Nike Air; new Nike Mind and Nike Free footwear, platforms built to scale across sport; innovation

Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 14:00:00 EET | Press release

Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over a mandrel for a snug fit and a defined ID before braiding, coiling, and jacketing, and the thin wa

2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 14:00:00 EET | Press release

The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “For generations, Bacardi has had a front-row seat to what’s next in drinks. By combining insights from bar teams, leading venues

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 11:00:00 EET | Press release

Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe a chance to catch up, and Plural believes the continent has the founders, research and momentum to build many more global companies of its own. Global companies, built from Europe When Plural launched in 2022, frontier founders working on defence, energy, space and AI infrastructure in Europe struggled to raise capital. Plural’s partners backed startups in these sectors early, and Plu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye